首页> 外文期刊>ACS medicinal chemistry letters >Interaction of Half Oxa-/Half cis-Platin Complex with Human Superoxide Dismutase and Induced Reduction of Neurotoxicity
【24h】

Interaction of Half Oxa-/Half cis-Platin Complex with Human Superoxide Dismutase and Induced Reduction of Neurotoxicity

机译:半氧化术与人超氧化物歧化酶的相互作用和诱导神经毒性的减少

获取原文
获取原文并翻译 | 示例
       

摘要

The formation of amorphous protein aggregates containing human superoxide dismutase (hSOD1) is thought to be involved in amyotrophic lateral sclerosis onset. cis-Platin inhibits the oligomerization of apo hSOD1, but its toxicity precludes any possible use in therapy. Herein, we propose a less toxic platinum complex, namely oxa/cis-platin, as hSOD1 antiaggregation lead compound. Oxa/cis-platin is able to interact with hSOD1 in the disulfide oxidized apo form by binding cysteine 111 (Cys111). The mild neurotoxic phenomena induced in vitro and in vivo by oxa/cis-platin can be successfully reverted by using lypoyl derivatives, which do not interfere with the antiaggregation properties of the platin derivative.
机译:认为含有人超氧化物歧化酶(HSOD1)的无定形蛋白质聚集体被认为参与肌萎缩侧面硬化发作。 CIS-铂抑制APO HSOD1的低聚,但其毒性排除了治疗中的任何可能使用。 在此,我们提出了毒性铂络合物,即Oxa / CIS-铂作为HSOD1抗凝聚铅化合物。 Oxa / CIS-铂能够通过结合半胱氨酸111(Cys111)与二硫化物氧化APO形式的HSOD1相互作用。 通过使用Lypoyl衍生物可以成功地再次促进体外和体内体内诱导的体外毒性现象,这不会干扰铂衍生物的抗凝聚性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号